SCHEMBL30666100

SCHEMBL30666100

CCC[C@@H](C)NCCc1ccc(F)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 3/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
TAAR1 Q96RJ0 1/20 0.52
OPRK1 P41145 2/20 0.50
HPGD P15428 2/20 0.47
ALDH1A1 P00352 2/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
SIGMAR1 Q99720 4/20 0.47
KDM4E B2RXH2 3/20 0.47
MAPK1 P28482 3/20 0.47
LMNA P02545 2/20 0.47
SLC22A1 O15245 1/20 0.47
CA12 O43570 1/20 0.47
EGFR P00533 1/20 0.47
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
LCK P06239 1/20 0.47
FYN P06241 1/20 0.47
CA3 P07451 1/20 0.47
ADRB2 P07550 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25588044 1.00 HTT (0.53) HTTSMN1; SMN2TAAR1OPRK1HPGD
SCHEMBL28873445 0.82 SIGMAR1 (0.68) HTTSMN1; SMN2OPRK1SIGMAR1CYP1A2
SCHEMBL30608659 0.81 TAAR1 (0.57) HTTSMN1; SMN2TAAR1OPRK1SIGMAR1
SCHEMBL3084431 0.80 TAAR1 (0.61) HTTSMN1; SMN2TAAR1HPGDL3MBTL1
SCHEMBL3359355 0.79 HTT (0.49) HTTSMN1; SMN2OPRK1SIGMAR1KDM4E
SCHEMBL19505482 0.77 SIGMAR1 (0.81) OPRK1SIGMAR1ADRB2ADRB1ADORA3
SCHEMBL10563230 0.76 SIGMAR1 (0.56) SIGMAR1
SCHEMBL20796231 0.76 TAAR1 (0.52) TAAR1OPRK1HPGDL3MBTL1SIGMAR1
SCHEMBL19080589 0.75 TAAR1 (0.55) HTTSMN1; SMN2TAAR1HPGDL3MBTL1
SCHEMBL25918452 0.75 SIGMAR1 (0.68) OPRK1SIGMAR1ADRB2ADRB1ADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12280023-B2 Fluorophenyl beta-hydroxyethylamines and their use in the treatment of hyperglycaemia ATROGI AB (SE) 2025-04-22 US disclosed
US-20230364035-A1 FLUOROPHENYL BETA-HYDROXYETHYLAMINES AND THEIR USE IN THE TREATMENT OF HYPERGLYCAEMIA ATROGI AB (SE) 2023-11-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12280023-B2 Fluorophenyl beta-hydroxyethylamines and their use in the treatment of hyperglycaemia GPR119, SLC5A2, SLC5A1 HTT 648/4885SMN1; SMN2 2130/4885TAAR1 1115/4885
US-20230364035-A1 FLUOROPHENYL BETA-HYDROXYETHYLAMINES AND THEIR USE IN THE TREATMENT OF HYPERGLYCAEMIA GPR119, SLC5A2, SLC5A1 HTT 648/4885SMN1; SMN2 2130/4885TAAR1 1115/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.